SIGNAL GRIDv0.1

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial - CNBC

2 sources2 storiesFirst seen 4/27/2026Score47Breakthrough
CoverageRecencyEngagementVelocityBignessConfidenceClipability
Bigness
47
Coverage
25
Recency
77
Engagement
21
Velocity
100
Confidence
63
Clipability
70
Polarization
0
Claims
4
Contradictions
0
Breakthrough
100

Sentiment Mix

Positive100%
Neutral0%
Negative0%

Geography

EuropeNorth America

Expert Signals

Politics - Google News US Headlines

source1 mention

Politics - Google News CA Headlines

source1 mention

AI-Generated Claims

Generated from linked receipts; click sources for full context.

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - Intellia Therapeutics.

Supported by 1 story

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing Intellia TherapeuticsIntellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial CNBCIntellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema Yahoo FinanceIntellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial statnews.comBuy the Rumor, Sell the News: Intellia (NTLA) Falls After Landmark Phase 3 Win CoinCentral

Supported by 1 story

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Supported by 1 story

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial CNBCIntellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing Intellia TherapeuticsIntellia begins FDA filing for CRISPR therapy lonvo-z for rare disease Investing.com CanadaIntellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 Yahoo FinanceIntellia reports positive Phase 3 trial results for HAE therapy By Investing.com Investing.com Canada

Supported by 1 story

Related Events

Timeline (2 stories)

Receipts (2)

Bias Snapshot

Center
Left 0%Center 100%Right 0%
Blognews.google.com4/27/2026
Blognews.google.com4/27/2026